APLS,Apellis Pharmaceuticals, Inc. | Healthcare

Healthcare

APLS

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Apellis Pharmaceuticals, Inc.APLS

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver.

It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.

The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Latest News >

EU to impose tariffs of up to 25% on Chinese EVs, FT reports

Jun 12, 2024

June 12 (Reuters) - The European Commission will notify car makers on Wednesday that it will provisionally apply additional duties of up to 25% on imported Chinese electric vehicles from next month, the Financial Times reported, citing people familiar with the matter. Analysts have said they expect tariffs of between 10% and 25% on Chinese EVs, a move likely to...

Warby Parker Insider Sold Shares Worth $1,275,122, According to a Recent SEC Filing

Jun 12, 2024

03:18 AM EDT, 06/12/2024 (MT Newswires) -- Neil Harris Blumenthal, Director, Co-Chief Executive Officer, on June 07, 2024, sold 76,582 shares in Warby Parker ( WRBY ) for $1,275,122. Following the Form 4 filing with the SEC, Blumenthal has control over a total of 412,177 shares of the company, with 12,177 shares held directly and 400,000 controlled indirectly. SEC Filing:...

Zillow Group Insider Bought Shares Worth $99,966,743, According to a Recent SEC Filing

Jun 12, 2024

03:17 AM EDT, 06/12/2024 (MT Newswires) -- Jay C Hoag, Director, on June 07, 2024, executed a purchase for 2,338,036 shares in Zillow Group ( ZG ) for $99,966,743. Following the Form 4 filing with the SEC, Hoag has control over a total of 5,955,569 shares of the company, with 9,116 shares held directly and 5,946,453 controlled indirectly. SEC Filing:...

Euro zone government bond yields drop ahead U.S. inflation data, Fed

Jun 12, 2024

June 12 (Reuters) - Euro zone government bond yields dropped on Wednesday as investors' focus shifted to the release of key U.S. inflation data and the outcome of the Federal Reserve policy meeting later in the session. French and Southern European borrowing costs had risen to their highest levels in around seven months on Tuesday on fears that gains by...